Lung function tests (or pulmonary function tests) include a variety of tests that check how well the lungs work.

New columnist Jolie Lizana shares her harrowing journey to a pulmonary hypertension diagnosis and finding purpose in advocacy ...

No description.

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price ...

The Saudi Food and Drug Authority (SFDA) has approved the registration of Winrevair (sotatercept) for the treatment of adult patients with World Health Organization (WHO) Functional Class II to III ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs ...

The pulmonary arterial hypertension market is expected to reach USD 2,080.7 million by 2025 and is expected to steadily grow at a CAGR of 2.3% to reach USD 2,612.0 million by 2035.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.